文献速递间质性肺疾病

Nerandomilast治疗特发性肺纤维化:FIBRONEER-IPF试验全随访期数据

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

FIBRONEER-IPF随机安慰剂对照试验中,1177例特发性肺纤维化患者接受nerandomilast 9 mg或18 mg每日两次或安慰剂治疗,随访至末例完成治疗访视。全随访期分析显示,nerandomilast对首次IPF急性加重、呼吸原因住院或死亡的复合终点无影响,但18 mg每日两次组死亡风险数值上较低。

要点

  • nerandomilast对首次IPF急性加重、呼吸原因住院或死亡的复合终点无显著影响
  • 18 mg每日两次组死亡风险数值上低于安慰剂组(HR 0.66,95%CI 0.41-1.08)
  • 因不良事件停药率低,安全性良好

核心结论

  • 在FIBRONEER-IPF试验全随访期中,nerandomilast对首次IPF急性加重、呼吸原因住院或死亡的复合终点无影响。
  • nerandomilast 18 mg每日两次与数值上较低的死亡风险相关。
  • nerandomilast安全性良好,因不良事件停药率低。

研究设计与样本

  • FIBRONEER-IPF随机安慰剂对照试验的全随访期分析,1177例患者接受治疗。
  • 患者随机接受安慰剂、nerandomilast 9 mg每日两次或18 mg每日两次,第52周后继续随机治疗直至末例完成治疗访视。
  • 平均(SD)试验药物暴露时间分别为安慰剂14.8(5.0)个月、nerandomilast 9 mg组14.9(5.0)个月、18 mg组14.7(5.3)个月。

主要发现

  • 与安慰剂相比,关键次要终点(首次IPF急性加重、呼吸原因住院或死亡)的风险比(95%CI)为nerandomilast 9 mg组0.92(0.69, 1.22)、18 mg组0.99(0.75, 1.31)。
  • 与安慰剂相比,死亡的风险比(95%CI)为nerandomilast 9 mg组0.95(0.61, 1.49)、18 mg组0.66(0.41, 1.08)。
  • 不良事件导致停药的比例在安慰剂组、nerandomilast 9 mg组和18 mg组分别为13.0%、13.5%和16.1%。

临床怎么用

  • 对于IPF患者,nerandomilast未能改善首次急性加重、呼吸原因住院或死亡的复合终点。
  • 18 mg每日两次方案在死亡风险上显示数值上的获益趋势,但需谨慎解读。
  • nerandomilast因不良事件停药率低,耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: In the randomized placebo-controlled FIBRONEER-IPF trial in patients with idiopathic pulmonary fibrosis, both nerandomilast 9 mg bid and 18 mg bid met the primary endpoint of reducing decline in forced vital capacity at week 52. Patients continued to receive randomized treatment after week 52, until the last patient had completed an end-of-treatment visit. OBJECTIVES: To assess the effects of nerandomilast over the full duration of follow-up in the FIBRONEER-IPF trial. METHODS: Time to first acute exacerbation of IPF, hospitalization for respiratory cause, or death (key secondary endpoint) and other time-to-event endpoints were assessed at final database lock. MEASUREMENTS AND MAIN RESULTS: 1177 patients were treated. Mean (SD) exposure to trial medication was 14.8 (5.0), 14.9 (5.0) and 14.7 (5.3) months in the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively. Compared with placebo, the hazard ratio (95% CI) for the key secondary endpoint was 0.92 (0.69, 1.22) for nerandomilast 9 mg bid and 0.99 (0.75, 1.31) for nerandomilast 18 mg bid and the hazard ratio (95% CI) for death was 0.95 (0.61, 1.49) for nerandomilast 9 mg bid and 0.66 (0.41, 1.08) for nerandomilast 18 mg bid. Adverse events led to treatment discontinuation in 13.0%, 13.5% and 16.1% of the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively. CONCLUSIONS: In the FIBRONEER-IPF trial, nerandomilast had no effect on the composite endpoint of time to first acute exacerbation of IPF, hospitalization for respiratory cause, or death, but nerandomilast 18 mg bid was associated with a numerically lower risk of death. Nerandomilast had a favorable safety profile, with a low rate of discontinuation due to adverse events.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026. PMID: 41738262. doi:10.1093/ajrccm/aamag058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。